Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech to Use GE Healthcare Dyes in Microarray Kits

This article has been corrected from a previous version that ran yesterday. GE Healthcare is providing the Cy3 and Cy5 dyes under the agreement, not the Universal Linkage System, which was developed by Kreatech. 

NEW YORK, Feb. 22 (GenomeWeb News) - Kreatech Biotechnology said yesterday that it has signed an agreement allowing it to use GE Healthcare's Cy3 and Cy5 dyes in combination with its Universal Linkage System in DNA microarray-labeling kits.

Under the terms of the agreement, Kreatech gains global rights for the use of Cy3 and Cy5 dyes with the Universal Linkage System in fluorescent applications within the life sciences market, Kreatech said. Kreatech will use the technology to develop and manufacture microarray-labeling kits for amplified RNA labeling and genomic DNA labeling, it said.

Kreatech said the technology enables direct DNA labeling, negating the need for modified nucleotides.

Financial terms of the deal were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.